Role of alpha-lipoic acid in the management of anemia in patients with chronic renal failure undergoing hemodialysis

International Journal of Nephrology and Renovascular Disease

Volumn 6, Issue , 2013, Pages 161-168

  El Nakib, Gehad A ^a   Mostafa, Tarek M ^b   Abbas, Tarek M ^d   El Shishtawy, Mamdouh M ^c   Mabrouk, Mokhtar M ^b   Sobh, Mohammed A ^d  

^a MANSOURA UNIVERSITY HOSPITAL   (Egypt)

^b TANTA UNIVERSITY   (Egypt)

^c MANSOURA UNIVERSITY   (Egypt)

^d MANSOURA UNIVERSITY   (Egypt)

Author keywords

Alpha lipoic acid; Anemia; Asymmetric dimethylarginine; Erythropoietin; Hemodialysis; Oxidative stress

Indexed keywords

ALBUMIN; CALCIUM; CREATINE; ERYTHROPOIETIN; HEMOGLOBIN; INTERLEUKIN 6; MALONALDEHYDE; N(G),N(G) DIMETHYLARGININE; NITROGEN; OXIDIZED LOW DENSITY LIPOPROTEIN; PARATHYROID HORMONE; PHOSPHORUS; RECOMBINANT ERYTHROPOIETIN; THIOACID; THIOCTIC ACID; TRANSFERRIN; TUMOR NECROSIS FACTOR ALPHA; UREA;

ADULT; ALBUMIN BLOOD LEVEL; ANEMIA; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; BLOOD SAMPLING; CALCIUM BLOOD LEVEL; CHRONIC KIDNEY FAILURE; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETES MELLITUS; ENDOTHELIAL DYSFUNCTION; FEMALE; HEMODIALYSIS; HEPATITIS C; HUMAN; IRON BINDING CAPACITY; IRON BLOOD LEVEL; MALE; OXIDATIVE STRESS; PHOSPHATE BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SMOKING; UREA NITROGEN BLOOD LEVEL;

EID: 84883650980     PISSN: None     EISSN: 11787058     Source Type: Journal    
DOI: 10.2147/IJNRD.S49066     Document Type: Article

References (53)

1. Furuland H, Linde T, Ahlmén J, Christensson A, Strömbom U, Danielson BG. A randomized controlled trial of haemoglobin normalization with epoetin alfa in pre-dialysis and dialysis patients. Nephrol Dial Transplant. 2003;18(2):353-361.
2. Ayus JC, Go AS, Valderrabano F, etal; Spanish Group for the Study of the Anemia and Left Ventricular Hypertrophy in Pre-dialysis Patients. Effects of erythropoietin on left ventricular hypertrophy in adults with severe chronic renal failure and hemoglobin, 10 g/dL. Kidney Int. 2005;68(2):788-795.
3. Frank H, Heusser K, Höffken B, Huber P, Schmieder RE, Schobel HP. Effect of erythropoietin on cardiovascular prognosis parameters in hemodialysis patients. Kidney Int. 2004;66(2):832-840.
4. Robinson BM, Joffe MM, Berns JS, Pisoni RL, Port FK, Feldman HI. Anemia and mortality in hemodialysis patients: accounting for morbidity and treatment variables updated over time. Kidney Int. 2005;68(5): 2323-2330.
5. KDOQI; National Kidney Foundation. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease. Am J Kidney Dis. 2006;47(Suppl 3):S11-S145.
6. Locatelli F, Aljama P, Bárány P, etal; European Best Practice Guidelines Working Group. Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant. 2004;19 Suppl 2:ii1-i47.
7. Singh AK. What is causing the mortality in treating the anemia of chronic kidney disease: erythropoietin dose or hemoglobin level? Curr Opin Nephrol Hypertens. 2010;19(5):420-424.
8. Regidor DL, Kopple JD, Kovesdy CP, etal. Associations between changes in hemoglobin and administered erythropoiesis-stimulating agent and survival in hemodialysis patients. J Am Soc Nephrol. 2006; 17(4):1181-1191.
9. Hodkova M, Dusilova-Sulkova S, Kalousova M, etal. Influence of oral vitamin E therapy on micro-inflammation and cardiovascular disease markers in chronic hemodialysis patients. Ren Fail. 2006;28(5): 395-399.
10. Boaz M, Smetana S, Weinstein T, etal. Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomised placebo-controlled trial. Lancet. 2000;356(9237): 1213-1218.
11. Morimoto H, Nakao K, Fukuoka K, etal. Long-term use of vitamin E-coated polysulfone membrane reduces oxidative stress markers in haemodialysis patients. Nephrol Dial Transplant. 2005;20(12): 2775-2782.
12. Yang CC, Hsu SP, Wu MS, Hsu SM, Chien CT. Effects of vitamin C infusion and vitamin E-coated membrane on hemodialysis-induced oxidative stress. Kidney Int. 2006;69(4):706-714.
13. Chan D, Irish A, Dogra G. Efficacy and safety of oral versus intravenous ascorbic acid for anaemia in haemodialysis patients. Nephrology (Carlton). 2005;10(4):336-340.
14. Hsu SP, Chiang CK, Yang SY, Chien CT. N-acetylcysteine for the management of anemia and oxidative stress in hemodialysis patients. Nephron Clin Pract. 2010;116(3):c207-c216.
15. Dashti-Khavidaki S, Khalili H, Barzegar E, etal. Effect of 4-week treatment with oral N-acetylcysteine on plasma homocysteine concentration and antioxidant activity of patients on chronic hemodialysis. Kidney. 2008;17(3):122-125.
16. Kamgar M, Zaldivar F, Vaziri ND, Pahl MV. Antioxidant therapy does not ameliorate oxidative stress and inflammation in patients with end-stage renal disease. J Natl Med Assoc. 2009;101(4):336-344.
17. Tarng D-C. How can erythropoietin requirements be reduced in dialysis patients? Semin Dial. 2006;19(5):367-369.
18. Bjelakovic G, Nikolova D, Gluud LL, Simonetti RG, Gluud C. Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: systematic review and meta-analysis. JAMA. 2007;297(8):842-857.
19. Huang KC, Yang CC, Hsu SP, etal. Electrolyzed-reduced water reduced hemodialysis-induced erythrocyte impairment in end-stage renal disease patients. Kidney Int. 2006;70(2):391-398.
20. Shay KP, Moreau RF, Smith EJ, Smith AR, Hagen TM. Alpha-lipoic acid as a dietary supplement: molecular mechanisms and therapeutic potential. Biochim Biophys Acta. 2009;1790(10):1149-1160.
21. [No author listed]. alpha-Lipoic acid. Altern Med Rev. 2006;11:232-237.
22. El-Beshbishy HA, Bahashwan SA, Aly HA, Fakher HA. Abrogation of cisplatin-induced nephrotoxicity in mice by alpha lipoic acid through ameliorating oxidative stress and enhancing gene expression of antioxidant enzymes. Eur J Pharmacol. 2011;668(1-2):278-284.
23. Sehirli O, Sener E, Cetinel S, Yüksel M, Gedik N, Sener G. Alpha-lipoic acid protects against renal ischaemia-reperfusion injury in rats. Clin Exp Pharmacol Physiol. 2008;35(3):249-255.
24. Kanter M, Sen S, Donmez S, Aktas C, Ustundag S, Erboga M. Protective effects of irbesartan and alpha lipoic acid in STZ-induced diabetic nephropathy in rats. Ren Fail. 2010;32(4):498-505.
25. Bhatti F, Mankhey RW, Asico L, Quinn MT, Welch WJ, Maric C. Mechanisms of antioxidant and pro-oxidant effects of alpha-lipoic acid in the diabetic and nondiabetic kidney. Kidney Int. 2005;67(4): 1371-1380.
26. Esterbauer H, Cheeseman KH. Determination of aldehydic lipid peroxidation products: malonaldehyde and 4-hydroxynonenal. Methods Enzymol. 1990;186:407-421.
27. López-Gómez JM, Portolés JM, Aljama P. Factors that condition the response to erythropoietin in patients on hemodialysis and their relation to mortality. Kidney Int Suppl. 2008:S75-S81.
28. Chang JW, Lee EK, Kim TH, etal. Effects of alpha-lipoic acid on the plasma levels of asymmetric dimethylarginine in diabetic end-stage renal disease patients on hemodialysis: a pilot study. Am J Nephrol. 2007;27(1):70-74.
29. Yilmaz A, Bekpinar S, Unlucerci Y, Gurdol F, Umman B. High concentrations of asymmetric dimethylarginine are associated with ST-segment resolution failure after reperfusion for acute myocardial infarction. Clin Chem Lab Med. 2011;49(5):903-907.
30. Wilson AM, Shin DS, Weatherby C, etal. Asymmetric dimethylarginine correlates with measures of disease severity, major adverse cardiovascular events and all-cause mortality in patients with peripheral arterial disease. Vasc Med. 2010;15(4):267-274.
31. Abedini S, Meinitzer A, Holme I, etal. Asymmetrical dimethylarginine is associated with renal and cardiovascular outcomes and all-cause mortality in renal transplant recipients. Kidney Int. 2010;77(1):44-50.
32. Zoccali C, Bode-Böger S, Mallamaci F, etal. Plasma concentration of asymmetric dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. Lancet. 2001;358(9299):2113-2117.
33. Lee WJ, Kim SW, Kim SH, etal. Alpha-lipoic acid activates dimethyl-arginine dimethylaminohydrolase in cultured endothelial cells. Biochem Biophys Res Commun. 2010;398(4):653-658.
34. Mittermayer F, Pleiner J, Francesconi M, Wolzt M. Treatment with alpha-lipoic acid reduces asymmetric dimethylarginine in patients with type 2 diabetes mellitus. Transl Res. 2010;155(1):6-9.
35. Singh U, Jialal I. Alpha-lipoic acid supplementation and diabetes. Nutr Rev. 2008;66(11):646-657.
36. Veresiu IA. Intravenous alpha-lipoic acid improves fructosamine level in type 2 diabetes patients. Acta Endocrinol (Buc). 2009;5(4):501-506.
37. Hong SB, Uhm WH, Joo WC, Nam MS, Lee SW, Song JH. Plasma markers of oxidative stress, inflammation and endothelial cell injury in diabetic patients with overt nephropathy administered alpha-lipoic acid and angiotensin II receptor blocker. Mol Cell Toxicol. 2010;6(2): 179-185.
38. Xiang G, Pu J, Yue L, Hou J, Sun H. α-lipoic acid can improve endothelial dysfunction in subjects with impaired fasting glucose. Metab Clin Exp. 2011;60(4):480-485.
39. Heinisch BB, Francesconi M, Mittermayer F, etal. Alpha-lipoic acid improves vascular endothelial function in patients with type 2 diabetes: a placebo-controlled randomized trial. Eur J Clin Invest. 2010;40(2): 148-154.
40. Morcos M, Borcea V, Isermann B, etal. Effect of alpha-lipoic acid on the progression of endothelial cell damage and albuminuria in patients with diabetes mellitus: an exploratory study. Diabetes Res Clin Pract. 2001;52(3):175-183.
41. Ziegler D, Nowak H, Kempler P, Vargha P, Low PA. Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a meta-analysis. Diabet Med. 2004;21(2):114-121.
42. d'Uscio LV, Smith LA, Santhanam AV, Richardson D, Nath KA, Katusic ZS. Essential role of endothelial nitric oxide synthase in vascular effects of erythropoietin. Hypertension. 2007;49(5):1142-1148.
43. Katavetin P, Tungsanga K, Eiam-Ong S, Nangaku M. Antioxidative effects of erythropoietin. Kidney Int Suppl. 2007:S10-S15.
44. Sakata T, Furuya R, Shimazu T, Odamaki M, Ohkawa S, Kumagai H. Coenzyme Q10 administration suppresses both oxidative and antioxidative markers in hemodialysis patients. Blood Purif. 2008;26(4): 371-378.
45. Stepniewska J, Dolegowska B, Ciechanowski K, Kwiatkowska E, Millo B, Chlubek D. Erythrocyte antioxidant defense system in patients with chronic renal failure according to the hemodialysis conditions. Arch Med Res. 2006;37(3):353-359.
46. Taccone-Galluci M, Lubrano R, Trapasso E, etal. Oxidative damage to RBC membranes and pentose phosphate shunt activity in hemodialysis patients after suspension of erythropoietin treatment. ASAIO J. 1994;40(3):M663-M666.
47. Paşaoǧlu H, Muhtaroǧlu S, Güneş M, Utaş C. The role of the oxidative state of glutathione and glutathione-related enzymes in anemia of hemodialysis patients. Clin Biochem. 1996;29(6):567-572.
48. Zachée P, Ferrant A, Daelemans R, Goossens W, Boogaerts MA, Lins RL. Reduced glutathione for the treatment of anemia during hemodialysis: a preliminary communication. Nephron. 1995;71(3):343-349.
49. Mirjana M, Jelena A, Aleksandra U, etal. Alpha-lipoic acid preserves the structural and functional integrity of red blood cells by adjusting the redox disturbance and decreasing O-GlcNAc modifications of antioxidant enzymes and heat shock proteins in diabetic rats. Eur J Nutr. 2012;51(8):975-986.
50. Khabbazi T, Mahdavi R, Safa J, Pour-Abdollahi P. Effects of alpha-lipoic acid supplementation on inflammation, oxidative stress, and serum lipid profile levels in patients with end-stage renal disease on hemodialysis. J Ren Nutr. 2012;22(2):244-250.
51. Khurana A, Nickel AE, Narayanan M, Foulks CJ. Effect of hepatitis C infection on anemia in hemodialysis patients. Hemodial Int. 2008; 12(1):94-99.
52. Lin YL, Lin CW, Lee CH, Lai IC, Chen HH, Chen TW. Chronic hepatitis ameliorates anaemia in haemodialysis patients. Nephrology (Carlton). 2008;13(4):289-293.
53. Weidemann A, Johnson RS. Nonrenal regulation of EPO synthesis. Kidney Int. 2009;75(7):682-688.